Veterinary Medicines

LINCEX SOLUCION INYECTABLE

Suspended
  • Spectinomycin sulfate tetrahydrate
  • Lincomycin hydrochloride
Download as PDF

Product identification

Medicine name:
LINCEX SOLUCION INYECTABLE
Active substance:
  • Spectinomycin sulfate tetrahydrate
  • Lincomycin hydrochloride
Target species:
  • Pig
  • Dog
  • Cattle (pre-ruminant)
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Spectinomycin sulfate tetrahydrate
    100.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Lincomycin hydrochloride
    50.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Meat and offal
        21
        day
    • Dog
    • Cattle (pre-ruminant)
      • Meat and offal
        21
        day
      • Milk
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01FF52
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Suspended
Authorised in:
  • Spain
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • S P Veterinaria S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • S P Veterinaria S.A.
Responsible authority:
  • Spanish Agency Of Medicines And Medical Devices
Authorisation number:
  • 2627 ESP
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 29/11/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."